Innovative Therapy Technology Leo Cancer Care is developing groundbreaking upright radiation therapy systems with plans to obtain FDA approval and CE mark, positioning it as a pioneering provider in accessible, patient-focused cancer treatment solutions.

Strategic Partnerships The company has recently partnered with TibaRay and expanded collaborations with renowned research institutions like Imperial College London and Institut Curie, signaling opportunities to introduce their innovative systems through established clinical networks and academic collaborations.

Market Expansion Potential With product launches such as the Grace upright photon therapy system showcased at major industry conferences like ASTRO 2025, Leo Cancer Care is establishing credibility that could drive adoption in top cancer centers worldwide once commercially available.

Funding and Growth Having secured $40 million in funding and demonstrating revenue growth between $10 million to $25 million, Leo Cancer Care is financially positioned to expand its sales efforts and accelerate product deployment in key markets.

Patient Engagement Initiatives The launch of support tools like Statue Quest for young radiation patients highlights a commitment to enhancing patient experience, making the company's offerings more attractive to healthcare providers prioritizing comprehensive, patient-centered care.